Department of Surgical Oncology, Taizhou Municipal Hospital, Taizhou, China.
Eur Rev Med Pharmacol Sci. 2019 Apr;23(7):2856-2862. doi: 10.26355/eurrev_201904_17563.
The aim of this study was to determine the role of microRNA-506-3p (miR-506) in papillary thyroid carcinoma (PTC), and to further explore the underlying mechanism.
The expression level of miR-506 in clinical cases was detected by Real Time-fluorescence quantitative Polymerase Chain Reaction (RT-qPCR). Meanwhile, RT-qPCR was performed to determine miR-506 expression in different PTC cell lines. Bioinformatics software was used to predict the possible target genes of miR-506. Dual-Luciferase reporter gene assay together with Western blot (WB) assay were used to verify the prediction results. Finally, cellular functions such as proliferation and metastasis capacities were detected in vitro.
RT-qPCR was used to measure the expression level of miR-506 in 80 paired PTC cases. The results showed that the expression level of miR-506 in PTC tissues was significantly decreased. In vitro, miR-506 expression was also markedly suppressed in four PTC cell lines. TPC-1 cells expressed the lowest level of miR-506. Subsequently, the target gene of miR-506 was predicted by TargetScan, miRBase and miRanda. The prediction results indicated that IL17RD was an alternative target gene of miR-506. Furthermore, miR-506 was found to remarkably inhibit the Luciferase activity of wild-type IL17RD. However, it had no effect on mutant-type. Besides, the protein expression level of IL17RD was significantly reduced in miR-506-overexpressing TPC-1 cells. More importantly, the restored expression of IL17RD could alleviate the blocking effects of miR-506 on cell proliferation, migration and invasion.
In this study, we found that miR-506 could inhibit the proliferation and metastasis of PTC cells. Meanwhile, IL17RD might be a downstream target of the biological process. Our findings provided a new therapeutic direction for the treatment of PTC.
本研究旨在探讨微小 RNA-506-3p（miR-506）在甲状腺乳头状癌（PTC）中的作用，并进一步探讨其潜在机制。
采用实时荧光定量聚合酶链反应（RT-qPCR）检测临床病例中 miR-506 的表达水平。同时，采用 RT-qPCR 检测不同 PTC 细胞系中 miR-506 的表达。采用生物信息学软件预测 miR-506 的可能靶基因。双荧光素酶报告基因检测和 Western blot（WB）检测用于验证预测结果。最后，在体外检测细胞增殖和转移能力等细胞功能。
采用 RT-qPCR 测量 80 对 PTC 病例中 miR-506 的表达水平。结果显示，PTC 组织中 miR-506 的表达水平显著降低。体外，四种 PTC 细胞系中 miR-506 的表达也明显受到抑制。TPC-1 细胞中 miR-506 的表达水平最低。随后，TargetScan、miRBase 和 miRanda 预测 miR-506 的靶基因。预测结果表明，IL17RD 是 miR-506 的替代靶基因。此外，miR-506 显著抑制野生型 IL17RD 的荧光素酶活性。然而，它对突变型没有影响。此外，miR-506 过表达的 TPC-1 细胞中 IL17RD 的蛋白表达水平显著降低。更重要的是，IL17RD 的恢复表达可减轻 miR-506 对细胞增殖、迁移和侵袭的阻断作用。
本研究发现，miR-506 可抑制 PTC 细胞的增殖和转移。同时，IL17RD 可能是该生物学过程的下游靶基因。我们的研究结果为 PTC 的治疗提供了新的治疗方向。
